ICMR has licensed the promising anti-cancer compound SHetA2, marking a significant step toward developing a new treatment for early-stage cervical cancer. Researchers say the therapy has shown encouraging preclinical results, with the potential to target cancer cells while minimizing damage to healthy tissue, though further clinical trials are needed before widespread use.